Prime Medicine announces research collaboration with Cimeio Therapeutics
The partnership is intended to combine Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 Jun 23
The partnership is intended to combine Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
23 Jun 23
Through the continued partnership, individuals affected by rare blood cancers, including various types of leukaemia, lymphoma, and myeloma,…
23 Jun 23
Now the iLet Bionic Pancreas is cleared for three insulins
22 Jun 23
Blincyto is a bispecific T-cell engager (BiTE) immuno-oncology therapy that targets CD19 surface antigens on B cells, to…
22 Jun 23
The primary focus of the funding will be to advance TGW101, Tagworks' leading click-cleavable ADC (Antibody-Drug Conjugate) programme,…
22 Jun 23
Umoja will leverage Ozette’s proprietary immune cell population discovery and annotation platform for novel oncology insights in preclinical…
22 Jun 23
Transformation has resulted in Ellab tripling its revenues, EBITDA and number of employees, while experiencing approximately 20% annual…
21 Jun 23
Dice Therapeutics leverages the Delscape technology platform to develop novel oral therapeutic candidates, including oral IL-17 inhibitors to…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Jun 23
The site is expected to feature new manufacturing equipment to increase the company's lamination capacity for materials like…
21 Jun 23
The collaboration aims to facilitate the commercialisation of PharmaTher's Ketarx (racemic ketamine) products in the US